Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | KMO | O15229 | 2/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17300858 | 0.83 | KIF11 (0.49) | IDO1CTSSCTSK | |
| SCHEMBL6407483 | 0.82 | KDM1A (0.39) | IDO1SCN2ACTSSCTSKXDH | |
| SCHEMBL785845 | 0.79 | KIF11 (0.45) | SCN2AMAOBKDM1ANOTUM | |
| SCHEMBL28200313 | 0.78 | XDH (0.59) | IDO1SCN2ACTSSCTSKKMO | |
| SCHEMBL1502415 | 0.77 | IDO1 (0.50) | IDO1KMOMAOBKDM4EMEN1 | |
| SCHEMBL24337281 | 0.77 | CYP11B2 (0.39) | — | |
| SCHEMBL30641499 | 0.77 | CYP11B2 (0.39) | — | |
| SCHEMBL5672965 | 0.76 | XDH (0.51) | CTSSCTSKXDH | |
| SCHEMBL18051397 | 0.75 | NOTUM (0.44) | CTSSCTSKKDM1ANOTUM | |
| SCHEMBL7156561 | 0.75 | IDO1 (0.53) | IDO1SCN2ACTSSCTSKKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | claimed |
| US-20140323740-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-10-30 | — | — | US | claimed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | claimed |
| CN-102083429-A | Ido inhibitors | NEWLINK GENETICS | 2011-06-01 | — | — | CN | claimed |
| CN-107108577-A | New compound | 奇斯药制品公司 | 2017-08-29 | — | — | CN | disclosed |
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140323740-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-10-30 | — | — | US | disclosed |
| US-8748469-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| CN-102083429-B | Ido inhibitors | NEWLINK GENETICS | 2014-05-28 | — | — | CN | disclosed |
| CN-101679439-B | P70S 6 kinase inhibitors | LILLY CO ELI | 2013-09-11 | — | — | CN | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| CN-102083429-A | Ido inhibitors | NEWLINK GENETICS | 2011-06-01 | — | — | CN | disclosed |
| CN-101679439-A | P70S 6 kinase inhibitors | LILLY CO ELI | 2010-03-24 | — | — | CN | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | IDO1 4787/4885SCN2A 889/4885CTSS 3082/4885 |
| US-20140323740-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885SCN2A 4411/4885CTSS 2421/4885 |
| US-20110136796-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885SCN2A 4411/4885CTSS 2421/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | IDO1 4787/4885SCN2A 889/4885CTSS 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.